2
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 2/3
1
Status
Unknown
1
Completed
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
15
Thoracic
4
Gastrointestinal
4
Plasma cell
3
Lymphoid
3
Head & Neck
3
Sarcoma
2
Other solid neoplasm
2
Genitourinary
2
Tumor-Agnostic
1
Other hematologic neoplasm
1
Gynecologic
1
CNS
1
Conditions
Motor Activity
2
Uterine Cervical Neoplasms
1
Sarcoma
1
Pancreatic Neoplasms
1
Head and Neck Neoplasms
1
Fatigue
1
Esophageal Neoplasms
1
Carcinoma, Bronchogenic
1
Brain Neoplasms
1
Bone Neoplasms
1
Interventions
Radiotherapy
220
Doxorubicin
210
Cyclophosphamide
210
Temozolomide
182
Ifosfamide
121
Filgrastim
111
Imatinib Mesylate
104
Etoposide
101
Vincristine
92
Gemcitabine
89
Bevacizumab
83
Magnetic Resonance Spectroscopy
80
Irinotecan
79
pembrolizumab
75
Radiation
69
Carboplatin
65
Methotrexate
62
pazopanib
61
Nivolumab
58
Cisplatin
58
fludarabine phosphate
57
Peripheral Blood Stem Cell Transplantation
57
Surgical Procedures, Operative
56
Specimen Handling
56
Trabectedin
52
Docetaxel
50
Biopsy
50
Busulfan
49
Melphalan
46
Paclitaxel
44
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Exercise Therapy
×
Sarcoma
×
Clear all
NCT04963517
2024-12-06
proGAIT
Universität Duisburg-Essen
Phase 2/3
Completed
11 enrolled
NCT04517019
2020-08-18
OnkoFit II
University Hospital Tuebingen
Phase NA
Unknown
201 enrolled